Physician profile
Christopher Todd Nelson
NPI 1558305029
$1,160.18
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $60.18 · 2021: $89.77 · 2022: $168 · 2023: $220 · 2024: $233 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $165.69 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $151.30 | 2021-2025 | |
| Exact Sciences Corporation | $110.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $107.11 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.39 | 2019-2025 | Jardiance |
| Abbvie INC. | $67.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.61 | 2020-2025 | Airsupra |
| Sanofi Pasteur INC. | $53.90 | 2023 | |
| Novo Nordisk INC | $47.78 | 2019-2024 | Rybelsus |
| Amgen INC. | $31.91 | 2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $31.33 | 2019-2023 | |
| Edwards Lifesciences Corporation | $28.54 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $26.93 | 2019-2022 | |
| Inspire Medical Systems, INC. | $25.48 | 2025 | Inspire |
| Cranial Technologies, INC | $22.58 | 2025 | Doc Band |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.25 | 2025 | Gvoke Hypopen |
| Insmed, INC. | $18.55 | 2019 | |
| Merck Sharp & Dohme LLC | $18.55 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Lilly USA, LLC | $17.72 | 2023 | Jardiance |
| Eisai INC. | $16.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.60 | 2024 | Nuedexta |
| Abbott Laboratories | $14.04 | 2023 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.